RVPH vs. CLLS, IMAB, CYBN, ATYR, CTMX, KPTI, ORMP, YS, ACRS, and SGMT
Should you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Cellectis (CLLS), I-Mab (IMAB), Cybin (CYBN), Atyr PHARMA (ATYR), CytomX Therapeutics (CTMX), Karyopharm Therapeutics (KPTI), Oramed Pharmaceuticals (ORMP), YS Biopharma (YS), Aclaris Therapeutics (ACRS), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry.
Cellectis (NASDAQ:CLLS) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
Cellectis has a beta of 3.1, meaning that its share price is 210% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.
63.9% of Cellectis shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 31.8% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cellectis presently has a consensus price target of $8.00, suggesting a potential upside of 247.83%. Reviva Pharmaceuticals has a consensus price target of $14.33, suggesting a potential upside of 1,046.67%. Given Cellectis' higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Cellectis.
Reviva Pharmaceuticals has a net margin of 0.00% compared to Reviva Pharmaceuticals' net margin of -529.81%. Reviva Pharmaceuticals' return on equity of -67.41% beat Cellectis' return on equity.
In the previous week, Cellectis had 3 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 4 mentions for Cellectis and 1 mentions for Reviva Pharmaceuticals. Cellectis' average media sentiment score of 0.93 beat Reviva Pharmaceuticals' score of 0.47 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.
Reviva Pharmaceuticals has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cellectis received 386 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 90.91% of users gave Reviva Pharmaceuticals an outperform vote while only 67.22% of users gave Cellectis an outperform vote.
Summary
Cellectis and Reviva Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Reviva Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reviva Pharmaceuticals Competitors List
Related Companies and Tools
